Journal of Otology & RhinologyISSN: 2324-8785

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
bahis siteleri bahis siteleri bahis siteleri casino siteleri

Results of an international, randomized clinical trial with a homeopathic medication in patients with recurrent tonsillitis

Kishchuk V V, Palm J, Keller T, Weber S, De Jaegere S and Klement P

Vinnytsia Regional Clinical Hospital, Ukraine

: J Otol Rhinol


Background & Aims: In the light of discussions regarding possible therapies of patients affected by a moderate Recurrent Tonsillitis (RT), for whom recent clinical guidelines recommend a watchful waiting period, the current clinical trial was performed. It assessed the effectiveness and safety of the homeopathic medicinal product SilAtro-5-90 in patients with moderate RT. Methods: The open-label randomized clinical trial was conducted in Germany, Spain and Ukraine in patients aged 6-60 years with moderate RT. The combined treatment of SilAtro-5-90 (Atropinum sulfuricum D5, Hepar sulfuris D3, Kalium bichromicum D4, Silicea D2, Mercurius bijodatus D8) and symptomatic medication (test group) was compared to symptomatic medication alone (control group). SilAtro-5-90 was given during 3 treatment periods of 8 weeks each. Endpoints were the mean period of time between consecutive Acute Throat Infections (ATI) within 1 year (analyzed via repeated events analysis), the number of days the patients were suffering from RT symptoms as well as the incidence of Adverse Events (AEs). Results: ITT population comprised 254 patients (86 patients <12 years, 51 patients from 12 to <18 years, 117 patients ≥18 years) with a moderate RT. The hazard of getting an ATI was significantly lower in the test group than in the control group (hazard ratio=0.45; 95%-CI: 0.34-0.60; p<0.0001; intensity model). Already during the first treatment period, patients in the test group were free of RT symptoms during significantly more days (MWU-test; p<0.0001). From the 225 AEs in the test group, 3 AEs (gastroenteritis, nausea and foul taste) were rated as related to SilAtro-5-90. Conclusion: Trial results indicate that SilAtro-5-90 may be a well-tolerated and effective therapeutic option in the treatment of moderate RT.


Kishchuk V V is the Professor of the Department of Otorhinolaryngology at Vinnitsa National Medical University. He is also the author and co-author of scientific publications, including textbooks for otolaryngology for students and interns, has 19 innovative proposals and 9 inventions.

E-mail: [email protected]

Track Your Manuscript

Media Partners